Skip to main content

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

NASDAQ: RVPH · IEX Real-Time Price · USD
3.50 0.02 (0.57%)
Oct 22, 2021 9:30 AM EDT - Market open
Market Cap47.53M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out12.87M
EPS (ttm)-0.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume518
Open3.50
Previous Close3.48
Day's Range3.50 - 3.50
52-Week Range3.29 - 15.10
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About RVPH

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and ps...

IndustryBiotechnology
Founded2006
Employees5
Stock ExchangeNASDAQ
Ticker SymbolRVPH
Full Company Profile

Financial Performance

Financial Statements

News

Reviva Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CUPERTINO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that ...

1 month ago - GlobeNewsWire

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights

-Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million

2 months ago - GlobeNewsWire

Reviva Pharma Stock Is Trading Higher After Maxim Initiated With Buy, Target Price Of $10

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) is trading higher with around 60k in session volume. Maxim initiated coverage of Reviva with a Buy rating and $10 price target, equivalent to an upside...

2 months ago - Benzinga

Reviva Added to Russell Microcap® Index

CUPERTINO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical compan...

3 months ago - GlobeNewsWire

Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering

CUPERTINO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that se...

4 months ago - GlobeNewsWire

RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday

Today, investors in RVPH stock saw some pretty massive gains, as the company announced impressive results for its schizophrenia drug. The post RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% ...

5 months ago - InvestorPlace

Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...

Other symbols:AXSMQUREVYGRCRSP
5 months ago - Benzinga

Here's why Reviva Pharmaceuticals soared more than 100% on Monday

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) more than doubled in value Monday after the clinical-stage biopharmaceutical company reported encouraging phase 2 clinical trial results fo...

5 months ago - Invezz

Reviva Pharma Stock Trading Higher On Detailed Positive Schizophrenia Study Results

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has announced the full details of its Phase 2 trial evaluating its lead drug candidate, RP5063 (brilaroxazine), for Acute Schizophrenia. Brilaroxazine ...

5 months ago - Benzinga

Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia

CUPERTINO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical compa...

5 months ago - GlobeNewsWire

Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update

-Closed Merger with Tenzing Acquisition Corp and publicly listed on  NASDAQ Capital Market-

7 months ago - GlobeNewsWire

Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Ph...

Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW

10 months ago - GlobeNewsWire

Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc.

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Tenzing Acquisition Corp.

1 year ago - PRNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Tenzi...

New York, New York--(Newsfile Corp. - July 24, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who own Tenzing Acquisition Corp.

1 year ago - Newsfile Corp